The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
Due to current health and safety precautions, hard copy mailing of IMF publications are temporarily delayed up to several weeks. However, digital versions of all IMF publications are available below.
October 29, 2018
This publication discusses the use of Kyprolis (carfilzomib)— a proteasome inhibitor—for the treatment of myeloma.
May 18, 2018
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
November 30, 2018
This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
May 20, 2019
This publication discusses peripheral neuropathy, which can be a complication of multiple myeloma or its treatments.
May 18, 2018
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda Oncology